Hutchison China MediTech reports preliminary Phase II data for fruquintinib in NSCLC

In October, Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) reported preliminary data from 17 patients with advanced, EGFR mutation-positive non-small cell lung cancer (NSCLC) in a

Read the full 253 word article

User Sign In